Delpharm, a CDMO, has expanded its pharmaceutical network with the acquisition of Astellas’ Meppel pharmaceutical manufacturing facility in the Netherlands.
 
The fully equipped facility with state-of-the-art technologies is 31,600 square meters and employs 410 qualified personnel who contribute to the production of solid dosage forms, such as tablets, capsules and pellets. The site produces more than 40 million finished products packaged annually.
 
Meppel site holds quality authorizations for exporting medicines globally, including the FDA certification for the U.S., and ISO 14001 and 45001 certifications.
 
“We are delighted to further expand our operations in the Netherland with this 3rd site. Thanks to the Meppel site acquisition, we will strengthen our position in the Netherlands where Delpharm already owns one manufacturing site in Bladel and an injectable drug development centre in Leiden,” said Nicolas Ragot, Managing Director of Delpharm.